Hundreds of malaria patients participating in a Phase 3 clinical trial in Gabon in West Africa were cured via a single dose of a treatment that utilizes four widely available malaria drugs, according ...

Early data from a Phase 2 clinical trial show a combination of immunotherapy medications can activate a robust immune ...

A new malaria drug, Ganaplacide/Lumefantrine, shows over 97% cure rates in trials. This treatment is effective even where ...

In 2022, the WHO hailed Novartis’ GanLum as the most promising non-artemisinin-based combination. The Swiss drugmaker ...

New research from scientists at the UCLA Jonsson Comprehensive Cancer Center showcases a novel combination therapy that could help cancer patients who have developed resistance to certain treatments.

In preclinical studies, researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School ...

A new antimalarial drug developed by Novartis is as effective as existing treatments and could help tackle rising drug ...

Dr. Ghyslain Mombo-Ngoma led a study in Gabon in which researchers gave a single-dose treatment combining an artemisinin with ...

Scientists have discovered a new potential treatment that has the ability to reverse antibiotic resistance in bacteria that cause conditions such as sepsis, pneumonia, and urinary tract infections.